Mereo BioPharma Group plc - Company Profile

BioCentury | Dec 18, 2020

Deals

Dec. 17 Quick Takes: Ultragenyx gains rights to Mereo’s setrusumab; plus Verily’s $700M raise, dMed’s listing plans, Virios’ IPO

...Editor Ultragenyx gains ex-Europe rights to Mereo’s setrusumabUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) licensed ex-European rights to setrusumab from Mereo BioPharma Group plc...

BioCentury | Oct 20, 2020

Management Tracks

J&J promotes Kumar; plus moves at Krystal, Design, Centogene, Lyndra, Mereo and Neoleukin

...venture money since its founding in 2015.Christine Fox will join oncology and rare disease company Mereo BioPharma Group plc...
...Therapeutics Inc. Wyzga will continue to serve on Mereo’s board. Danielle Golovin Krystal Biotech Inc. Design Therapeutics Centogene N.V. Lyndra Therapeutics Inc. Mereo BioPharma Group plc Neoleukin...

BioCentury | Jul 3, 2020

Management Tracks

Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more

...the pandemic warning team for the U.S. Department of Defense. Oncology and rare diseases company Mereo BioPharma Group plc...
...Institute for Biomedical Research Akcea Therapeutics Inc. Oncopeptides AB Codiak BioSciences Inc. ImmVira Co. Ltd. Kyowa Kirin Co. Ltd. Inovio Pharmaceuticals Inc. Mereo BioPharma Group plc Leo...

BioCentury | Jun 4, 2020

Finance

TIGIT program drives OrbiMed-led $70M raise as Mereo looks to Phase Ib

...in convertible loan notes, which are exercisable at 34.8p for a period of three years. Mereo BioPharma Group plc...
...TIGIT - T cell immunoreceptor with Ig and ITIM domains Elizabeth S. Eaton, Staff Writer etigilimab (Anti-TIGIT; OMP-313M32) Mereo BioPharma Group plc T...

BioCentury | Feb 10, 2020

Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...$190.0 Oxford Nanopore Technologies Ltd. $184.6 Cell Medica Ltd. $151.5 Autolus Therapeutics plc (NASDAQ:AUTL) $135.5 Mereo BioPharma Group plc...

BioCentury | Dec 21, 2019

Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

...Chrono Therapeutics Inc., and Kapoun was SVP of translational medicine at OncoMed Pharmaceuticals Inc., which Mereo BioPharma Group plc...

BioCentury | Dec 11, 2019

Company News

Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more

...clinical development. Li was VP of finance, principle financial/accounting officer at OncoMed Pharmaceuticals Inc., which Mereo BioPharma Group plc...

BioCentury | Oct 19, 2019

Finance

Woodford’s empire crumbles. U.K biotech stays standing

...$190.0 Oxford Nanopore Technologies Ltd. $184.6 Cell Medica Ltd. $151.5 Autolus Therapeutics plc (NASDAQ:AUTL) $135.5 Mereo BioPharma Group plc...

BioCentury | Jun 15, 2019

Company News

June 13 Company Quick Takes: ISS rebuffs Takeda’s Weber; plus Sage, Blueprint, Tetraphase, Celgene and more

...NASDAQ:CELG) will not exercise an option to license anti-TIGIT mAb etigilimab from OncoMed Pharmaceuticals Inc. Mereo BioPharma Group plc...

BioCentury | May 24, 2019

Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...offerings; (C) Orchard Therapeutics plc (NASDAQ:ORTX) raised $225.5 million in an IPO in 2018; (D) Mereo BioPharma Group plc...
...Small molecules, precision medicine Cardiovascular Adaptimmune Ltd. (NASDAQ:ADAP) (D) $130.0 9/25/14 TCR T-cell therapies Cancer Mereo BioPharma Group plc...

Items per page:

1 - 10 of 20

BioCentury | Dec 18, 2020

Deals

Dec. 17 Quick Takes: Ultragenyx gains rights to Mereo’s setrusumab; plus Verily’s $700M raise, dMed’s listing plans, Virios’ IPO

...Editor Ultragenyx gains ex-Europe rights to Mereo’s setrusumabUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) licensed ex-European rights to setrusumab from Mereo BioPharma Group plc...

BioCentury | Oct 20, 2020

Management Tracks

J&J promotes Kumar; plus moves at Krystal, Design, Centogene, Lyndra, Mereo and Neoleukin

BioCentury | Jul 3, 2020

Management Tracks

Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more

BioCentury | Jun 4, 2020

Finance

TIGIT program drives OrbiMed-led $70M raise as Mereo looks to Phase Ib

BioCentury | Feb 10, 2020

Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...$190.0 Oxford Nanopore Technologies Ltd. $184.6 Cell Medica Ltd. $151.5 Autolus Therapeutics plc (NASDAQ:AUTL) $135.5 Mereo BioPharma Group plc...

BioCentury | Dec 21, 2019

Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

...Chrono Therapeutics Inc., and Kapoun was SVP of translational medicine at OncoMed Pharmaceuticals Inc., which Mereo BioPharma Group plc...

BioCentury | Dec 11, 2019

Company News

Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more

...clinical development. Li was VP of finance, principle financial/accounting officer at OncoMed Pharmaceuticals Inc., which Mereo BioPharma Group plc...

BioCentury | Oct 19, 2019

Finance

Woodford’s empire crumbles. U.K biotech stays standing

...$190.0 Oxford Nanopore Technologies Ltd. $184.6 Cell Medica Ltd. $151.5 Autolus Therapeutics plc (NASDAQ:AUTL) $135.5 Mereo BioPharma Group plc...

BioCentury | Jun 15, 2019

Company News

June 13 Company Quick Takes: ISS rebuffs Takeda’s Weber; plus Sage, Blueprint, Tetraphase, Celgene and more

...NASDAQ:CELG) will not exercise an option to license anti-TIGIT mAb etigilimab from OncoMed Pharmaceuticals Inc. Mereo BioPharma Group plc...

BioCentury | May 24, 2019

Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

Items per page:

1 - 10 of 20

Dec. 17 Quick Takes: Ultragenyx gains rights to Mereo’s setrusumab; plus Verily’s $700M raise, dMed’s listing plans, Virios’ IPO

J&J promotes Kumar; plus moves at Krystal, Design, Centogene, Lyndra, Mereo and Neoleukin

Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more

TIGIT program drives OrbiMed-led $70M raise as Mereo looks to Phase Ib

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more

Woodford’s empire crumbles. U.K biotech stays standing

June 13 Company Quick Takes: ISS rebuffs Takeda’s Weber; plus Sage, Blueprint, Tetraphase, Celgene and more

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

Dec. 17 Quick Takes: Ultragenyx gains rights to Mereo’s setrusumab; plus Verily’s $700M raise, dMed’s listing plans, Virios’ IPO

J&J promotes Kumar; plus moves at Krystal, Design, Centogene, Lyndra, Mereo and Neoleukin

Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more

TIGIT program drives OrbiMed-led $70M raise as Mereo looks to Phase Ib

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more

Woodford’s empire crumbles. U.K biotech stays standing

June 13 Company Quick Takes: ISS rebuffs Takeda’s Weber; plus Sage, Blueprint, Tetraphase, Celgene and more

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

Products & Solutions

About Biocentury

Contact

Privacy & Legal